Retatrutide.

Quick Overview.

Retatrutide (LY3437943) is an investigational triple-hormone-receptor agonist currently in Phase 3 clinical trials for the treatment of obesity and type 2 diabetes. It targets three distinct receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCGR). This "triple G" agonism provides synergistic effects, leading to unprecedented weight loss and significant improvements in metabolic health,[3] including substantial reductions in liver fat.[5]

Primary Use Case: Extreme weight loss, metabolic syndrome correction, and liver fat reduction. Who it is for: Individuals with severe obesity or those who have plateaued on dual agonists like tirzepatide, pending regulatory approval.

The Protocol & Usage Guide.

Before you start: Retatrutide is currently an unapproved, investigational drug. The protocols below reflect clinical trial designs and community practices.

Reconstitution: Typically acquired as a lyophilized powder requiring reconstitution with bacteriostatic water. Injection Site: Subcutaneous injection in the abdomen, thigh, or upper arm. Rotate sites weekly. Missed Dose: If a dose is missed and the next scheduled dose is more than 2 days away, administer the missed dose as soon as possible. If less than 2 days, skip the missed dose and resume the regular schedule.

Community Consensus: community Users often start at 1 mg or 2 mg and titrate up slowly (e.g., every 4 weeks) to mitigate gastrointestinal side effects and increased heart rate. Many find that 4 mg or 8 mg provides sufficient weight loss without needing the maximum 12 mg dose.[1]

Nutritional Support & Recommended Supplements.

• Protein: High protein intake (1.5-2.0g/kg body weight) is critical to preserve lean muscle mass during rapid and extreme weight loss.
• Hydration: Increased water intake is necessary to prevent dehydration, especially if experiencing nausea or vomiting.
• Electrolytes: Supplementation may be needed if dietary intake is significantly reduced.

Safety, Interactions & Side Effect Management.

Side Effects:

• Nausea, vomiting, diarrhea, constipation (Very Common, well-established)
• Increased heart rate (Common, emerging)
• Fatigue, headache (Common, emerging)

Contraindications (Absolute):

• Personal or family history of medullary thyroid carcinoma (MTC) (Theoretical, based on GLP-1 class)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) (Theoretical, based on GLP-1 class)

Contraindications (Relative):

• History of pancreatitis
• Severe gastrointestinal disease
• Pre-existing arrhythmias or tachycardia

Red Flags:

• Severe, persistent abdominal pain (potential pancreatitis)
• Sustained, significantly elevated resting heart rate[4]

Pregnancy/Lactation/Fertility:

• No data available. Likely contraindicated during pregnancy based on class effects.

Common Stacks & Combinations.

Retatrutide is extremely potent and is generally used as a standalone therapy.

Anti-Pattern Stacks:

Body Composition & Training Guide.

Retatrutide leads to rapid and significant reductions in body weight.[3] Resistance training is absolutely essential to mitigate the loss of lean mass.

Contexts:

• Hypertrophy: Extremely difficult due to severe caloric deficit. Focus entirely on muscle maintenance.
• Fat Loss: Unprecedented efficacy, surpassing current dual agonists.[6]

Storage, Handling & Accessibility.

• Storage (Unreconstituted/Unopened): Refrigerate at 2°C to 8°C (36°F to 46°F).
• Storage (Reconstituted/Opened): Can be kept at room temperature (up to 30°C/86°F) or refrigerated for up to 56 days (based on similar peptides).
• Accessibility: Currently an investigational drug. Available only through clinical trials or research chemical suppliers.

Bloodwork Monitoring Guide.

Baseline Panel:

• Comprehensive Metabolic Panel (CMP)
• Lipid Panel
• HbA1c
• Thyroid Stimulating Hormone (TSH)
• Resting Heart Rate and ECG (recommended due to GCGR agonism)

Mid-Cycle (3-6 months):

• Re-evaluate HbA1c and Lipid Panel.[4]
• Monitor renal function (BUN/Creatinine) if experiencing severe GI symptoms.
• Monitor resting heart rate.

Doctor Handoff Note: "Patient is utilizing retatrutide, an investigational triple-agonist (GLP-1/GIP/GCGR), for weight management. Please monitor for signs of pancreatitis, gallbladder disease, changes in renal function, and specifically monitor resting heart rate and cardiovascular status due to the glucagon receptor agonism."

Comparison to Similar Compounds.

Deep Dive (For Advanced Researchers).

Retatrutide is a single peptide engineered to activate the GLP-1, GIP, and glucagon receptors. The addition of glucagon receptor agonism is hypothesized to increase energy expenditure and significantly enhance hepatic fat clearance compared to GLP-1/GIP dual agonists.

Mechanism of Action: It binds to and activates the GLP-1R, GIPR, and GCGR. GLP-1 and GIP agonism improve glycemic control and reduce appetite. GCGR agonism increases energy expenditure and promotes hepatic lipid metabolism. emerging[2]

Clinical Trials:

Active Metabolites: No data available.

Open Questions: Long-term cardiovascular safety, particularly regarding the sustained increase in resting heart rate observed in Phase 2 trials. The durability of weight loss post-discontinuation.

Frequently Asked Questions (FAQ).

1. Is retatrutide approved by the FDA? No, it is currently an investigational drug in Phase 3 clinical trials.[7]
2. How much weight can I lose? Phase 2 trials showed up to 24.2% weight loss at 48 weeks on the highest dose.
3. What makes it different from tirzepatide? It adds glucagon receptor agonism, which may increase energy expenditure and further reduce liver fat.
4. Does it increase heart rate? Yes, clinical trials have noted dose-dependent increases in resting heart rate [3].
5. What are the most common side effects? Nausea, diarrhea, vomiting, and constipation, similar to other incretin therapies.
6. Can I switch from tirzepatide to retatrutide? This is done in clinical practice, but requires careful dose adjustment and monitoring.
7. Does it cause muscle loss? Rapid weight loss includes both fat and lean mass; resistance training is essential.

International Regulatory Status.

Decision Tree.

[Goal: Extreme Weight Loss?]
   |--(No)--> STOP. Retatrutide is primarily for severe obesity.
   |--(Yes)--> [History of Medullary Thyroid Carcinoma or MEN 2?]
                 |--(Yes)--> STOP. Absolute contraindication.
                 |--(No)--> [Pre-existing arrhythmias or tachycardia?]
                              |--(Yes)--> STOP. GCGR agonism increases heart rate.
                              |--(No)--> [Willing to use an unapproved, investigational drug?]
                                           |--(No)--> Consider approved alternatives like Tirzepatide or Semaglutide.
                                           |--(Yes)--> Retatrutide is a strong candidate. Start at 1.0 mg or 2.0 mg/week.

What we cited.